We Expect The Stability In J&J's Stock To Continue

Johnson & Johnson?s stock has barely moved following its Q2 2015 earnings announcement, as there was nothing unexpected or groundbreaking. Currency headwinds were a dampener in otherwise what was a quarter of modest operational growth. We previously stated that with Remicade going off patent and Olysio?s sales plummeting, J&J needs new catalysts to drive growth. It appears that its current drugs such as Simponi, Stelara, Zytiga, etc., are barely managing to pull off that role. This is likely to ...